Crescita Therapeutics‘  subsidiary, Intega Skin Sciences, has acquired the Alyria skincare line from Sanofi Consumer Health Inc.

Crescita Therapeutics is a dermatology company that markets non-prescription skincare products and prescription drug products.

Alyria is a non-prescription line of medical skincare products sold into medical spas. Alyria’s products, two of which are shown above, complement Intega’s Pro-Derm product offering and will be sold through Crescita’s existing sales force.

Crescita purchased Alyria for cash consideration of $1.7 million, consisting of a combination of fixed cash installments, of which $0.8 million will be paid in 2017, as well as a royalty agreement based on a threshold of annual net sales of Alyria  over a nine-year period starting in 2020.

“This acquisition provides Crescita with a number of immediate benefits, including synergies in leveraging our sales and marketing infrastructure and know-how, increasing our manufacturing capacity utilization and increasing our product offering to international markets. In addition, we gain more than 200 new customers to expand the sales reach of our existing product lines,” said Serge Verreault, Crescita’s President.